Related Experiment Video
Updated: May 22, 2025
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Stroke Prevention in Atrial Fibrillation: A systematic Review and Meta-Analysis of Left Atrial Appendage Occlusion
Sangharsha Thapa1, Bishal Mandal2, Sangam Shah2
1From the Department of Neurology, Westchester Medical Center, New York Medical College, Valhalla, NY.
Insights
Left atrial appendage occlusion (LAAO) and direct oral anticoagulants (DOACs) offer comparable stroke prevention in atrial fibrillation. LAAO demonstrated superior safety, reducing major bleeding and mortality risks without increasing intracranial bleeding.
Area of Science:
- Cardiology
- Interventional Cardiology
- Public Health
Background:
- Atrial fibrillation (AF) elevates ischemic stroke risk, with thrombi often forming in the left atrial appendage (LAA).
- Direct oral anticoagulants (DOACs) are standard for stroke prevention in AF.
- Left atrial appendage occlusion (LAAO) presents a non-pharmacologic alternative, especially for high-bleeding-risk patients.
Purpose of the Study:
- To compare the efficacy and safety of LAAO versus DOACs for stroke prevention in atrial fibrillation patients.
- To evaluate thromboembolic events, bleeding risks, and mortality rates between LAAO and DOACs.
Main Methods:
- Systematic review and meta-analysis of 15 studies (1 RCT, 14 observational).
- Included 22,420 patients: 10,704 undergoing LAAO and 11,716 on DOACs.
- Compared rates of thromboembolic events, major bleeding, cardiovascular mortality, all-cause mortality, and intracranial bleeding.
Main Results:
- Comparable thromboembolic event rates between LAAO and DOACs.
- LAAO showed significantly lower risks of stroke/TIA (RR: 0.86), major bleeding (HR: 0.74), cardiovascular mortality (HR: 0.57), and all-cause mortality (RR: 0.66).
- The composite outcome favored LAAO (HR: 0.67); no significant difference in intracranial bleeding.
Conclusions:
- LAAO is a safe and effective alternative to DOACs for stroke prevention in atrial fibrillation, particularly beneficial for high-risk bleeding patients.
- LAAO demonstrates significant reductions in major bleeding and mortality compared to DOACs.
- Further research may solidify LAAO's role in managing AF-related stroke risk.
Abstract:
Atrial fibrillation significantly increases the risk of ischemic stroke, with thrombi primarily originating in the left atrial appendage (LAA). While direct oral anticoagulants (DOACs) are the standard for stroke prevention, LAA occlusion (LAAO) has emerged as a nonpharmacologic alternative, particularly for patients at high bleeding risk. A systematic review and meta-analysis included 15 studies (1 randomized control trial and 14 observational studies) encompassing 22,420 patients (10,704 LAAO, 11,716 DOAC). LAAO and DOACs demonstrated comparable thromboembolic event rates. LAAO was associated with significantly lower risks of stroke/transient ischemic attack (risk ratio: 0.86, P = 0.0004), major bleeding [hazard ratio (HR): 0.74, P = 0.03], cardiovascular mortality (HR: 0.57, P < 0.00001), and all-cause mortality (risk ratio 0.66, P = 0.006). The composite outcome significantly favored LAAO (HR: 0.67, P = 0.0008). No significant difference was found in intracranial bleeding rates.
